Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
$0.00
$0.02
$9K0.7912,688 shs900 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.99
+3.1%
$1.83
$1.33
$2.89
$58.84M1.75279,531 shs228,309 shs
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
$38.00
$37.94
$2.61
$38.90
$1.77B4.41.98 million shsN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$4.08
+3.0%
$3.50
$1.94
$5.65
$215.39M0.38386,226 shs264,990 shs
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$7.00
$7.10
$4.07
$7.70
$294.54M0.99133,095 shs12,421 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%+150.00%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
+1.05%+6.04%-3.50%+33.10%+10.29%
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
0.00%0.00%0.00%0.00%0.00%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
+2.59%+1.02%-5.71%+80.82%-9.38%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.1419 of 5 stars
3.51.00.00.00.63.30.6
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.1364 of 5 stars
3.54.00.04.20.61.70.6
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.00955.28% Upside
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
0.00
N/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.00
Buy$14.00244.40% Upside
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.78M1.02N/AN/A($0.06) per share-33.17
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
$14.87M119.01N/AN/A$4.13 per share9.20
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$36.33M5.91N/AN/A$0.27 per share15.06
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
$3.63M81.14N/AN/A$0.83 per share8.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
-$137.20M-$3.92N/AN/AN/A-554.71%-75.84%-49.08%N/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/A

Latest FPRX, SCPH, FBIO, EVLO, and TLC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
N/AN/AN/AN/AN/A
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
N/A
5.35
5.35
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.86
5.48
4.61
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.67
3.01
3.01

Institutional Ownership

CompanyInstitutional Ownership
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
67.28%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
89.52%
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
0.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable
Five Prime Therapeutics, Inc. stock logo
FPRX
Five Prime Therapeutics
8746.57 millionN/AOptionable
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3052.79 million50.27 millionOptionable
Taiwan Liposome Company, Ltd. stock logo
TLC
Taiwan Liposome
2,02042.08 millionN/ANot Optionable

Recent News About These Companies

What is the TLC Diet?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0005 0.00 (0.00%)
As of 02:32 PM Eastern

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.99 +0.06 (+3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$1.95 -0.04 (-2.01%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Five Prime Therapeutics stock logo

Five Prime Therapeutics NASDAQ:FPRX

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.

scPharmaceuticals stock logo

scPharmaceuticals NASDAQ:SCPH

$4.08 +0.12 (+3.03%)
Closing price 04:00 PM Eastern
Extended Trading
$4.07 -0.01 (-0.34%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Taiwan Liposome stock logo

Taiwan Liposome NASDAQ:TLC

Taiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan.